(Original in Japanese)
To whom it may concern,PharmaBio Corporation (Headquarter: Nagoya, Aichi; President and CEO: Hitoshi Kusano;hereinafter "PharmaBio") and ROHTO Pharmaceutical Co., Ltd. (Headquarter: Osaka City;
President: Masashi Sugimoto; hereinafter "Rohto Pharmaceutical") have entered into a joint
research agreement, aimed at carrying out the collaborative research on brand-new cell sheets
by using PharmaBio’s cell sheet manufacturing technology and Rohto Pharmaceutical’s cells
and culture media.

PharmaBio has developed a human (allogenic) subcutaneous adipose tissue derivedmesenchymal stem cell sheet, one of PharmaBio’s regenerative medicine products, by using
its own unique technology to manufacture a cell sheet composed only of extracellular matrix
components that the cells themselves produce and entered the clinical trial phase on patients
suffering from myopic chorioretinal atrophy (Phase I/IIa clinical trial) for the time being.
Rohto Pharmaceutical has proceeded with the developments of cell preparations composed ofhuman adipose tissue derived mesenchymal stem cells and serum free media bringing out thecapability of adipose tissue derived mesenchymal stem cells, as well.
At this joint research, PharmaBio will develop brand-new cell sheets with Rohto
Pharmaceutical’s cells and serum free media by the cell sheet manufacturing technology andperform characteristic analysis of the developed cell sheets.
Rohto Pharmaceutical and PharmaBio will aim at the further progress of the cell sheet
technology and the expansion of their clinical applications at this joint research.
It is expected that the joint research, which is aimed at the improvement of patients’ QOL
through most advanced medical technology and innovative approach, will become theimportant step for results of both companies’ R&D activities over years to bear fruit.

【About PharmaBio Corporation】
Ever since established in October 2010, PharmaBio's main business is development ofregenerative medicine products, development of manufacturing processes and contract
manufacturing of cellular pharmaceuticals, and contract testing and inspection services suchas cellular microbiological safety testing. PharmaBio started contract manufacturing businessof regenerative medicine products ahead of other companies in 2011 and have been providing
GMP/GCTP compliant services to global companies and others. Based on its solid
manufacturing knowledge, PharmaBio is engaged in the development of new regenerative
medicine products as well as high quality contract manufacturing services.
PharmaBio Corporation: https://www.pharmabio.co.jp/en/index.html【About ROHTO Pharmaceutical Co., Ltd.】In 1899, ROHTO Pharmaceutical Co., Ltd. was founded as started sales of "Ikatsu," agastrointestinal medicine, to help the increasing number of people suffering from stomach
diseases, which was becoming a health issue at the time. Since then, “health” has been Rohto’s
core value and we have been expanding our businesses from our core area of health & beauty
centered on over-the counter (OTC) drugs and skincare products to functional foods, primaryindustries such as agriculture and food businesses such as restaurants, and recently
regenerative medicine as well by promoting cutting edge life science research.
ROHTO Pharmaceutical Co., Ltd.：https://www.rohto.co.jp/global/【Please contact below for any question】
PharmaBio Corporation
E-mail：ir_admin@pharmabio.co.jp
ROHTO Pharmaceutical Co., Ltd.
E-mail：pr@rohto.co.jp